ArticleUnited European gastroenterology journal2018
Acquisition of double mutation in
Article in United European gastroenterology journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- First regional consensus on the management ofWorld journal of gastroenterology · 2025Guideline
- Pooled it
- Helicobacter pylori Management in Older Adults: Current Perspectives From Japan.The Korean journal of helicobacter and upper gastrointestinal research · 2026Review
- Third-Line and Later Susceptibility-GuidedJournal of clinical medicine · 2026Article
- Differences and trends in worldwide clinical guidelines forTranslational gastroenterology and hepatology · 2026Review
- Efficacy of a 7-day vonoprazan, sitafloxacin, and amoxicillin triple therapy as a fourth-line salvage regimen for refractory Helicobacter pylori infection.BMC gastroenterology · 2025Article
- Exploring Alternative Treatment Choices for Multidrug-Resistant Clinical Strains ofMicroorganisms · 2023Article
- Mutations Related to Antibiotics Resistance inAntibiotics (Basel, Switzerland) · 2023Article
- Efficacy and safety of low-dose rifabutin-based 7-day triple therapy as a third- or later-line Helicobacter pylori eradication regimen.Helicobacter · 2022Article
- Establishment of a reference panel of Helicobacter pylori strains for antimicrobial susceptibility testing.Helicobacter · 2022Article
- Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications.Nature reviews. Gastroenterology & hepatology · 2021Review
- Sitafloxacin for Third-LineJournal of clinical medicine · 2021Review
- Single-capsule bismuth quadruple therapy: preferable at the moment, but what should be next?United European gastroenterology journal · 2021Article
- Pulmonary infection due to fluoroquinolone-resistant Mycolicibacterium fortuitum: a case report.BMC infectious diseases · 2020Article
- High Antibiotic Resistance ofMicroorganisms · 2020Article
- Update on quinolone-containing rescue therapies forWorld journal of gastroenterology · 2020Review
- Vonoprazan-Based Third-Line Therapy Has a Higher Eradication Rate against Sitafloxacin-Resistant Helicobacter pylori.Cancers · 2019Article
- Neutrophil-activating Protein Polymorphism of Helicobacter pylori Determines the Host Risk of Dyspepsia.Cellular and molecular gastroenterology and hepatology · 2019Article
- Alternative eradication regimens forInfection and drug resistance · 2019Article
- Second-line rescue treatment ofWorld journal of gastroenterology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimAlthough sitafloxacin (STFX)-containing regimens are effective rescue treatments for
methodsWe conducted a retrospective, non-randomized study to compare the minimum inhibitory concentrations (MICs) of STFX and the location of
resultsA total of 266 patients treated with STFX-containing regimens for third-line
conclusionAcquisition of double mutations in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.